As the market is in a state of recovery, with some assets recording high and positive returns, some assets have been in ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Sabarimala Master Plan, emphasising cultural preservation, ecological restoration and better facilities for pilgrims, has ...

Transportation Secretary Jaime Bautista said the department is nearing a resolution to the right-of-way issue of Phase 2 of ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

It’s part of a plan Mayor Joe Hogsett first announced in 2022 to revitalize the downtown space, including the market itself.

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat ...

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

With an aggregate of $11 million raised in an initial Series A funding round, Doron Therapeutics is advancing its lead ...

The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...